Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891521 | 1.00 | HPGD (0.39) | HPGDL3MBTL1USP2SMN1; SMN2ADORA1 | |
| SCHEMBL30453762 | 1.00 | HPGD (0.39) | HPGDL3MBTL1USP2SMN1; SMN2ADORA1 | |
| SCHEMBL29211282 | 0.92 | USP2 (0.40) | USP2SMN1; SMN2ADORA1CYP11B2ACACB | |
| SCHEMBL24360840 | 0.90 | MEN1 (0.36) | HPGDL3MBTL1USP2SMN1; SMN2ADORA1 | |
| SCHEMBL631060 | 0.89 | HPGD (0.42) | HPGDL3MBTL1USP2SMN1; SMN2ADORA1 | |
| SCHEMBL16095519 | 0.88 | HPGD (0.38) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28838677 | 0.86 | HPGD (0.36) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14377883 | 0.85 | HPGD (0.36) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3157569 | 0.85 | HPGD (0.41) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21749171 | 0.84 | HPGD (0.42) | HPGDL3MBTL1USP2SMN1; SMN2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192833-B1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2026-01-21 | — | — | EP | disclosed |
| US-12473293-B2 | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2025-11-18 | — | — | US | disclosed |
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2023-09-14 | — | — | US | disclosed |
| EP-4192833-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | GABRA5, GABRA1, P2RX5 | HPGD 1106/4885L3MBTL1 4823/4885USP2 4591/4885 |
| US-12473293-B2 | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, GABRA1, P2RX5 | HPGD 1106/4885L3MBTL1 4823/4885USP2 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.